Abstract
Background
Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, many breast cancer patients with tumors expressing ER are unresponsive to aromatase inhibitors, and all patients with advanced disease eventually develop resistance to the therapy.
Methods
Twenty-one postmenopausal women with Stage II to IV breast cancer were treated with aromatase inhibitors as first-line endocrine therapy without surgery. Expression levels of ER, progesterone receptor, HER2 and Ki67 were examined by immunohistochemistry, and correlations between response and duration of the therapy and these levels were analyzed.
Results
Patients whose tumors contained two thirds or more ER-positive cells effectively responded to aromatase inhibitors (P = 0.006) and displayed longer time to progression during first-line endocrine therapy (P = 0.003) and longer time to endocrine therapy failure (P = 0.02). Patients whose tumors showed less than 15% Ki67 labeling index also displayed longer time to progression (P = 0.003).
Conclusion
High ER expression and low Ki67 expression were associated with improved time to progression with aromatase inhibitors as first-line endocrine therapy. Our findings will be helpful when endocrine therapy is planned in either early stage or advanced breast cancer.
Similar content being viewed by others
Abbreviations
- ER:
-
Estrogen receptor
- PgR:
-
Progesterone receptor
- HER2:
-
Human epidermal growth factor receptor type 2
- CR:
-
Complete response
- PR:
-
Partial response
- SD:
-
Stable disease
- IHC:
-
Immunohistochemistry
- Ki67 LI:
-
Ki67 labeling index
References
Iwase H (2008) Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15:278–290
Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784–3796
Cardoso F, Senkus-Konefka E, Fallowfield L et al (2010) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):15–19
Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol 23:2477–2492
Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
Yamashita H, Takahashi S, Ito Y et al (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100:2028–2033
Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816
Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065
Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 9:23–28
(2005) General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer 12 Supplement 2005:S8
Yamashita H, Nishio M, Toyama T et al (2008) Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15:755–763
Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319–1329
Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183
Rosa FE, Caldeira JR, Felipes J et al (2008) Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 39:720–730
Viale G, Regan MM, Maiorano E et al (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 25:3846–3852
Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575
Kai K, Nishimura R, Arima N et al (2006) p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11:426–433
Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176
Penault-Llorca F, Andre F, Sagan C et al (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2809–2815
Viale G, Regan MM, Mastropasqua MG et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100:207–212
Conflict of interest
All authors have no conflict of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Endo, Y., Toyama, T., Takahashi, S. et al. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol 16, 512–518 (2011). https://doi.org/10.1007/s10147-011-0215-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-011-0215-5